

Table SII. Illness behaviour, analysed by Scale for the Assessment of Illness Behavior (SAIB), for 92 patients with primary cutaneous lymphoma

SAIB	<i>n</i>	Mean ± standard deviation	Lower border 95% CI	Upper border 95% CI	Min-Max	<i>F</i> (df1, df2)	<i>p</i> -value	Cronbach's α
<i>Verification of diagnosis</i>								
IA-IIA early	36	12.94 ± 2.976	11.94	13.95	8-19	1.17 (3, 88)	0.327	0.624
IIB-IVB advanced	19	14.42 ± 2.714	13.11	15.73	8-19			
Non-mycosis fungoides (MF)/Sézary syndrome	13	12.77 ± 3.961	10.38	15.16	5-19			
Cutaneous B-cell lymphoma	24	13.29 ± 2.758	12.13	14.46	7-18			
Total	92	13.32 ± 3.034	12.69	13.94	5-19			
<i>Expression of symptoms</i>								
IA-IIA early	36	18.14 ± 3.356	17.00	19.27	11-24	0.96 (3, 88)	0.417	0.641
IIB-IVB advanced	19	19.37 ± 2.565	18.13	20.60	15-24			
Non-mycosis fungoides/Sézary syndrome	13	18.77 ± 3.295	16.78	20.76	13-23			
Other cutaneous B-cell lymphoma	24	17.96 ± 2.742	16.80	19.12	12-22			
Total	92	18.43 ± 3.043	17.80	19.06	11-24			
<i>Treatment/medication</i>								
IA-IIA early	36	12.69 ± 2.660	11.79	13.59	6-18	0.54 (3, 88)	0.656	0.605
IIB-IVB advanced	19	13.11 ± 2.622	11.84	14.37	8-19			
Non-mycosis fungoides/Sézary syndrome	13	12.15 ± 3.313	10.15	14.16	8-19			
Cutaneous B-cell lymphoma	24	12.13 ± 2.968	10.87	13.38	8-20			
Total	92	12.55 ± 2.810	11.97	13.14	6-20			
<i>Consequences</i>								
IA-IIA early	36	13.94 ± 2.937	12.95	14.94	8-19	0.54 (3, 88)	0.659	0.589
IIB-IVB advanced	19	13.63 ± 2.191	12.58	14.69	10-18			
Non-mycosis fungoides/Sézary syndrome	13	14.23 ± 3.113	12.35	16.11	6-18			
Cutaneous B-cell lymphoma	24	14.67 ± 2.988	13.40	15.93	8-19			
Total	92	14.11 ± 2.819	13.52	14.69	6-19			
<i>Scanning</i>								
IA-IIA early	36	9.06 ± 2.402	8.24	9.87	5-15	1.06 (3, 88)	0.371	0.738
IIB-IVB advanced	19	9.53 ± 3.062	8.05	11.00	5-15			
Non-mycosis fungoides/Sézary syndrome	13	9.15 ± 2.703	7.52	10.79	5-15			
Cutaneous B-cell lymphoma	24	8.21 ± 2.167	7.29	9.12	5-13			
Total	92	8.95 ± 2.539	8.42	9.47	5-15			

IA-IIA: early-stage MF; IIB-IVB: advanced-stage MF and Sézary syndrome (SS); non-MF/SS includes cutaneous T-cell lymphoma subtypes other than MF/SS; CI: confidence interval.